Anxiety Disorders - Viable Indication for Antipsychotics Companies
 From Drug Week - Jan 09, 2009
2009 JAN 9 - (NewsRx.com) -- Research and Markets  has announced the 
addition of the "Anxiety Disorders - Viable Indication for 
Antipsychotics Companies" report to their offering. Despite forming 
the mainstay of pharmacological treatment of anxiety disorders, 
response rates to serotonergic-based treatments are often less than 
robust. As such, physicians are increasingly looking towards novel drugs.


"People Who experience mood swings, fear, voices and visions"